Marcus Gail Boxer, a director at Natera, Inc. (NASDAQ:NTRA), recently sold a portion of his holdings in the company. According to a filing with the Securities and Exchange Commission, Boxer sold a total of 2,212 shares of Natera’s common stock on November 14, 2024. The shares were sold at prices ranging from $156.754 to $162.04 per share, resulting in a total transaction value of approximately $350,671.
Following these transactions, Boxer holds 19,386 shares of Natera. The sales were conducted over multiple transactions, as detailed in the filing. This activity comes as part of Boxer’s ongoing management of his investment portfolio.
In other recent news, Natera Inc (NASDAQ:). has been the subject of multiple analyst upgrades following robust financial results. The company reported a record Q3 revenue of $439.8 million, a 64% increase year-over-year, and a substantial rise in oncology test volumes with 137,000 tests performed, marking a 54% increase from the previous year. Notably, Natera’s gross margins reached a record 62%, and the company generated a cash flow of $34.5 million. Based on these strong financial results, Natera has revised its full-year revenue guidance upwards to between $1.61 billion and $1.64 billion.
In response to these developments, TD Cowen, Baird, and Jefferies have all expressed confidence in Natera’s operational success and future growth. TD Cowen raised its price target on Natera’s stock to $175, while Baird increased its target to $160, and Jefferies boosted its target to $182.
The company’s Signatera test, a key revenue-contributing product, showed promising results in predicting overall survival and chemotherapy benefits in colorectal cancer. Despite challenges with private payers and potential holiday-related disruptions in Q4, Natera sees significant growth opportunities ahead, with over 100 trials underway.
InvestingPro Insights
While Marcus Gail Boxer’s recent sale of Natera, Inc. (NASDAQ:NTRA) shares may raise questions, it’s important to consider the broader context of the company’s performance and market position. According to InvestingPro data, Natera’s stock has shown remarkable strength, with a 176.58% price total return over the past year and a significant 133.17% return year-to-date. This impressive performance aligns with the company’s robust revenue growth, which stands at 54.94% for the last twelve months as of Q3 2024.
InvestingPro Tips highlight that Natera operates with a moderate level of debt and its liquid assets exceed short-term obligations, suggesting a solid financial foundation. However, investors should note that the company is not currently profitable, with a negative operating income of $242.09 million in the last twelve months. Despite this, analysts remain optimistic, with 6 analysts revising their earnings upwards for the upcoming period.
The stock’s volatility, as indicated by another InvestingPro Tip, may explain why insiders like Boxer might choose to realize gains. With Natera trading at a high Price / Book multiple of 21.95, some may view the current price levels as an opportunity to rebalance portfolios.
For investors seeking a more comprehensive analysis, InvestingPro offers 14 additional tips for Natera, providing deeper insights into the company’s financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
